Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | PRCP | P42785 | 5/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1545744 | 0.84 | TSHR (0.65) | TSHRNPSR1SLC6A2SLC6A4OPRM1 | |
| SCHEMBL3060010 | 0.82 | TSHR (0.71) | TSHRNPSR1SLC6A2SLC6A4OPRM1 | |
| SCHEMBL9637870 | 0.82 | TSHR (0.71) | TSHRNPSR1SLC6A2SLC6A4OPRM1 | |
| SCHEMBL12571279 | 0.82 | TSHR (0.71) | TSHRNPSR1SLC6A2SLC6A4OPRM1 | |
| SCHEMBL12571281 | 0.82 | TSHR (0.71) | TSHRNPSR1SLC6A2SLC6A4OPRM1 | |
| SCHEMBL4022286 | 0.82 | TSHR (0.75) | TSHRNPSR1SLC6A2SLC6A4OPRM1 | |
| SCHEMBL4853532 | 0.81 | TSHR (0.60) | TSHRNPSR1SLC6A2SLC6A4OPRM1 | |
| SCHEMBL23119015 | 0.81 | TSHR (0.60) | TSHRNPSR1SLC6A2SLC6A4OPRM1 | |
| SCHEMBL514422 | 0.80 | TSHR (0.97) | TSHRNPSR1SLC6A2SLC6A4OPRM1 | |
| SCHEMBL574702 | 0.80 | TSHR (0.97) | TSHRNPSR1SLC6A2SLC6A4OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102803210-A | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV | 2012-11-28 | — | — | CN | claimed |
| US-20220409592-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2022-12-29 | — | — | US | disclosed |
| CN-102803210-A | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV | 2012-11-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220409592-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | CRHR1, CRHR2, MC2R | TSHR 267/4885NPSR1 32/4885SLC6A2 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.